New Mexico Educational Retirement Board purchased a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 20,000 shares of the biotechnology company’s stock, valued at approximately $2,305,000.
A number of other hedge funds have also modified their holdings of the company. Quadrant Capital Group LLC boosted its stake in Corcept Therapeutics by 1.3% during the 3rd quarter. Quadrant Capital Group LLC now owns 14,007 shares of the biotechnology company’s stock worth $1,650,000 after acquiring an additional 178 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Corcept Therapeutics by 1.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 10,617 shares of the biotechnology company’s stock valued at $923,000 after purchasing an additional 184 shares in the last quarter. State of Wyoming increased its stake in Corcept Therapeutics by 29.5% in the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares in the last quarter. Wedmont Private Capital increased its stake in Corcept Therapeutics by 6.1% in the third quarter. Wedmont Private Capital now owns 3,329 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 190 shares in the last quarter. Finally, Choreo LLC boosted its position in shares of Corcept Therapeutics by 8.0% during the third quarter. Choreo LLC now owns 4,190 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 312 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.
Corcept Therapeutics Stock Performance
Shares of CORT stock opened at $74.53 on Thursday. The company has a market capitalization of $8.16 billion, a P/E ratio of 57.76 and a beta of 0.54. The company’s 50 day moving average price is $105.23 and its two-hundred day moving average price is $76.16. Corcept Therapeutics Incorporated has a 52 week low of $28.66 and a 52 week high of $126.38.
Analyst Ratings Changes
CORT has been the subject of several research analyst reports. Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. HC Wainwright restated a “buy” rating and issued a $165.00 price objective on shares of Corcept Therapeutics in a research report on Friday, September 18th. Piper Sandler reaffirmed an “overweight” rating and set a $173.00 price objective (up from $165.00) on shares of Corcept Therapeutics in a research note on Wednesday, November 4th. Canaccord Genuity Group lifted their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Weiss Ratings upgraded Corcept Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $139.50.
Read Our Latest Stock Analysis on Corcept Therapeutics
Insider Activity at Corcept Therapeutics
In other Corcept Therapeutics news, insider Joseph Lyon sold 9,190 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $116.13, for a total transaction of $1,067,234.70. Following the completion of the transaction, the insider owned 5,683 shares in the company, valued at approximately $659,966.79. This represents a 61.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sean Maduck sold 13,159 shares of Corcept Therapeutics stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $82.25, for a total value of $1,082,327.75. Following the completion of the sale, the insider directly owned 9,938 shares in the company, valued at $817,400.50. This represents a 56.97% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 365,205 shares of company stock valued at $41,439,575. 20.70% of the stock is owned by insiders.
About Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
